Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress ...
Presentation to highlight SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORIN™ rapamycin 3.9% ...
Q4 2024 Palvella Therapeutics Inc Earnings Call
Bohan Wei; Vice President of Corporate Development & New Product Planning; Palvella Therapeutics Inc. Wesley Kaupinen; President, Chief Executive Officer, Director; ...
The Manila Times6 天
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
Top-line results from SELVA, a Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel ...